Latest Retail Investors News

Caspin Resources has successfully completed a $6 million placement and exercised options, bolstering its position in promising Australian mineral projects focused on tin and gold.

Latitude Group Holdings is considering launching a new Capital Notes 2 offer, potentially allowing existing CN1 holders to reinvest. The offer will require applications through appointed Syndicate Brokers under updated regulatory rules.

Oneview Healthcare has successfully raised A$19 million through a two-tranche placement and launched a Security Purchase Plan to further strengthen its financial position and accelerate AI development.

PYC Therapeutics has successfully closed its retail entitlement offer, raising approximately $47 million at $1.50 per new share with a 40% take-up rate. New shares are set to begin trading on the ASX from 9 March 2026.

FBR Limited reports a significant reduction in half-year losses alongside new robotic product launches, yet cash flow challenges raise questions about its financial sustainability.

Horizon Minerals has successfully raised A$175 million through a two-tranche institutional placement, complemented by a planned A$10 million share purchase plan, to fund the development of its Black Swan Processing Hub near Kalgoorlie.

29Metals has successfully completed the retail portion of its entitlement offer, raising $31 million and finalising a $150 million capital injection to support its growth ambitions.

TradeWindow has successfully closed its NZ$5.9 million Share Purchase Plan, with retail investors contributing around NZ$217,000. Shares will be allotted at NZ$0.25 each, matching the previous placement price.

Brightstar Resources has launched a $5 million Share Purchase Plan offering eligible shareholders discounted shares to fund key mining projects. The offer opens on 10 February and closes on 27 February 2026.

Kalamazoo Resources has successfully closed an oversubscribed Share Purchase Plan, raising $4.1 million to fast-track drilling and development at its Ashburton Gold Project. Combined with a recent placement, the company secures $12.1 million to advance exploration and pre-feasibility studies.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.